<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00388947</url>
  </required_header>
  <id_info>
    <org_study_id>1012</org_study_id>
    <nct_id>NCT00388947</nct_id>
  </id_info>
  <brief_title>Observational Data Collection of Surgical Outcomes in the Treatment of Vaginal Prolapse With AMS Products</brief_title>
  <acronym>POWER1012</acronym>
  <official_title>The Prolapse Registry: An Observational Collection of Short- and Long-Term Patient Outcomes Following Use of AMS Surgical Devices for the Repair of Female Genital Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ASTORA Women's Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ASTORA Women's Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry was observational (only collected information typically noted by the surgeon
      when their patients were routinely seen); there was no change to the care the patient
      received as a result of being part of the registry). Data collection focused on the surgical
      outcomes of AMS prolapse products.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Prolapse Registry was an observational study of patients who were implanted with AMS
      devices for the surgical repair of female pelvic prolapse. The registry followed patients
      post-operatively for up to 2 years and collected demographic, clinical, surgical, safety, and
      patient outcomes data.

      The registry was a web-based system in which surgeons entered patient information with regard
      to their prolapse surgery. All information entered was de-identified (no names, no date of
      birth, no date of surgery, etc).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Count of Patients With at Least One Adverse Event Related to Any AMS Prolapse Device</measure>
    <time_frame>up to 2-years post-implant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prolapse Efficacy Success Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Success was defined as either (1) Baden-Walker grade 0 or 1 or (2) (Pelvic Organ Prolapse Quantification System) POP-Q stage 0 or 1. If a site reported both measurements, then the POP-Q score was used.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1543</enrollment>
  <condition>Vaginal Prolapse</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>AMS Prolapse Product (AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AMS Prolapse Product</intervention_name>
    <description>AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Apogee, Straight-In, Perigee, Elevate anterior, Elevate Posterior</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female subjects greater than or equal to 21 years of age with genital prolapse who undergo
        surgical reconstruction of the pelvic floor using an AMS Prolapse Repair device.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female at least 21 years old

          -  Has pelvic organ prolapse requiring surgical repair

          -  Receives at least one of the AMS Prolapse Repair devices in the treatment of their
             pelvic organ prolapse

        Exclusion Criteria:

          -  Is contraindicated for an AMS Prolapse Repair per the product's Instruction for Use.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Zylstra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Whitinsville Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samuel Zylstra, MD</name>
      <address>
        <city>Whitinsville</city>
        <state>Massachusetts</state>
        <zip>01588</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2006</study_first_submitted>
  <study_first_submitted_qc>October 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2006</study_first_posted>
  <results_first_submitted>August 3, 2012</results_first_submitted>
  <results_first_submitted_qc>October 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2012</results_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaginal prolapse</keyword>
  <keyword>cystocele</keyword>
  <keyword>rectocele</keyword>
  <keyword>enterocele</keyword>
  <keyword>apical prolapse</keyword>
  <keyword>vaginal vault prolapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Uterine Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient was registered in September 2006, The last patient data were entered in May 2010.</recruitment_details>
      <pre_assignment_details>Patients had to met all of the inclusion criteria and none of the exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 - Any AMS Prolapse Product</title>
          <description>at least one AMS prolapse product was used</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1590"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1543">47 patients excluded because no AMS prolapse device was noted.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 - Any AMS Prolapse Product</title>
          <description>at least one AMS prolapse product was used</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1590"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Patients &gt;89 years old were excluded because protected health information was not collected in this study. Mean age excludes patients &gt;89 years old. Two patients were &gt;89 years old.</description>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age &lt;89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Count of Patients With at Least One Adverse Event Related to Any AMS Prolapse Device</title>
        <time_frame>up to 2-years post-implant</time_frame>
        <population>All patients that met the inclusion/exclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>1 - Any AMS Prolapse Product</title>
            <description>at least one AMS prolapse product was used</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Patients With at Least One Adverse Event Related to Any AMS Prolapse Device</title>
          <population>All patients that met the inclusion/exclusion criteria.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prolapse Efficacy Success Rate</title>
        <description>Success was defined as either (1) Baden-Walker grade 0 or 1 or (2) (Pelvic Organ Prolapse Quantification System) POP-Q stage 0 or 1. If a site reported both measurements, then the POP-Q score was used.</description>
        <time_frame>24 months</time_frame>
        <population>Patients returning for a visit between 19-24 months post-procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>1 - Any AMS Prolapse Product</title>
            <description>at least one AMS prolapse product was used</description>
          </group>
        </group_list>
        <measure>
          <title>Prolapse Efficacy Success Rate</title>
          <description>Success was defined as either (1) Baden-Walker grade 0 or 1 or (2) (Pelvic Organ Prolapse Quantification System) POP-Q stage 0 or 1. If a site reported both measurements, then the POP-Q score was used.</description>
          <population>Patients returning for a visit between 19-24 months post-procedure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" lower_limit="77.0" upper_limit="85.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 - Any AMS Prolapse Product</title>
          <description>at least one AMS prolapse product was used</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Extrusion</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="1543"/>
              </event>
              <event>
                <sub_title>Other Genitourinary</sub_title>
                <description>1)Coumadin medicated patient received too much anticoagulation therapy resulting in bleeding 2)small separation of anterior mesh from vaginal mucosa</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1543"/>
              </event>
              <event>
                <sub_title>Pain - dyspareunia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1543"/>
              </event>
              <event>
                <sub_title>Pain - excluding dyspareunia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1543"/>
              </event>
              <event>
                <sub_title>Wound separation &lt;3 months post-op</sub_title>
                <description>Wound separation events less than 3 months post-procedure including mesh exposure events</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1543"/>
              </event>
              <event>
                <sub_title>Perforation - bladder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Adhesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence</sub_title>
                <description>includes denovo and recurrent incontinence</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1543"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1543"/>
              </event>
              <event>
                <sub_title>Urinary urge, frequency, or hesistancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prolapse</sub_title>
                <description>includes denovo and recurrent</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Granuloma formation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Dehiscence at vaginal suture line before healing occurs</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>extrusion</sub_title>
                <description>mesh exposure through vaginal mucosa</description>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="1543"/>
              </event>
              <event>
                <sub_title>pain (excluding dyspareunia)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>incontinence</sub_title>
                <description>Includes both denovo and worsening incontinence</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>prolapse</sub_title>
                <description>includes denovo and recurrent prolapse</description>
                <counts group_id="E1" events="41" subjects_affected="40" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>granuloma formation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1543"/>
              </event>
              <event>
                <sub_title>other events below threshold</sub_title>
                <description>Incongruous events that are individually below the threshold</description>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>hematoma</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1543"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AMS (sponsor) is the sole owner of the conglomerate data inputted into the POWER database and has the right to publish such data at its sole discretion. Registry Physician will provide AMS with a copy of any data, finding, result, article, abstract, manuscripts, presentation, or other information intended for publication, at least thirty (30) days prior to submission of same for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Samuel Zylstra</name_or_title>
      <organization>Whitinsville Medical Center</organization>
      <phone>508-243-6260</phone>
      <email>samuelzylstra@milreg.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

